There’s some promising news on the horizon.
Researchers are optimistic that a new drug might provide hope for patients battling a particularly lethal type of breast cancer, potentially setting a new standard for treatment and boosting survival rates.
Clinical trials involving Trodelvy, an antibody-drug conjugate often referred to as a “smart bomb,” indicate that it outperformed chemotherapy for patients diagnosed with advanced triple-negative breast cancer who couldn’t opt for immunotherapy.
“This study presents strong evidence that Trodelvy surpasses chemotherapy as a first-line treatment for those newly diagnosed with metastatic triple-negative breast cancer,” said a medical professional from Lenox Hill Hospital, although he wasn’t part of the research.
Breast cancer ranks as the second most prevalent cancer among women in the United States—just after skin cancer. In fact, you could say about 1 in 8 women will receive this diagnosis at some point in their lives.
Triple-negative breast cancer (TNBC) is particularly aggressive, lacking the three typical receptors in cancer cells, which means standard hormone therapies won’t be effective.
About 15% of breast cancer cases fall into the TNBC category.
Alarmingly, roughly 42% of TNBC patients see a recurrence within five years, which is about three times the risk compared to other breast cancer types.
A recent study pointed out that merely 15% of TNBC patients with metastatic disease survive five years post-diagnosis.
In the trial, participants with advanced, inoperable, or metastatic TNBC who hadn’t previously undergone systemic treatment were given either Trodelvy or chemotherapy.
Patients receiving Trodelvy experienced a progression-free survival of 9.7 months, compared to just 6.9 months for those on chemotherapy.
The mechanism of Trodelvy involves targeting tumor surface proteins, as explained by the medical expert.
“Once it binds to cancer cells, Trodelvy is absorbed and released inside the cell, maximizing the destruction of tumor cells while mostly preserving healthy tissue. This precise action is why it’s referred to as a ‘smart bomb,’ and it contributes to its efficacy and safety,” he noted.
Findings suggested that Trodelvy leads to a more lasting response than chemotherapy (12.2 months versus 7.2 months).
“These outcomes support Trodelvy as a possible new standard treatment for advanced TNBC, offering significant improvements over traditional chemotherapy,” he remarked.
Throughout the trial, just 4% of patients stopped taking Trodelvy due to side effects, compared to 12% of those opting for chemotherapy.
Experts argue this enhances the drug’s relevance in real-world scenarios.
“Trodelvy showed consistent effectiveness across various patient groups, even among those with complicated cases like liver metastases and early recurrences,” he added.
The medical expert emphasized that chemotherapy has been the go-to treatment for TNBC for quite some time, despite its limited effectiveness and harsh side effects.
“Trodelvy is essential as it offers more lasting control of the disease, minimizes the toxic effects associated with standard chemotherapy—like peripheral neuropathy—and maintains or improves patients’ quality of life. It also supports early disease stabilization, making patients eligible for further treatments,” he explained.
He referred to the progress made with treatments like Trodelvy as a “paradigm shift in medicine,” expressing hope that if approved, it could save and extend lives.
“Trodelvy might genuinely save lives moving forward. Overall survival benefits have been seen in late-stage TNBC patients, and earlier application could enhance outcomes even more.”
Trodelvy contributes to patient survival in a few critical ways:
- It slows the disease’s progression at vital stages.
- It boosts the chances of subsequent treatments, which is crucial for survival.
- It reduces side effects, helping patients maintain function and reserves.
“Incorporating Trodelvy earlier in the treatment process could help patients not only live longer but live better. This is a significant advance for a group of patients that has been underserved historically.”
A prior study had found that using Trodelvy alongside Merck’s immunotherapy Keytruda decreased the risk of TNBC advancement by 35%.
